Researchers from Proqr Therapeutics NV recently presented preclinical data on AX-0810, a single-stranded RNA editing oligonucleotide (EON) targeting RNA coding for NTCP cotransporter ...

胆汁酸（Bile acid, ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

Are you searching for medications to treat 'Cholestatic Jaundice'? Welcome to this page which serves as an archive for medications that are relevant to the treatment of Cholestatic Jaundice.

Pathways of Hepatocyte Apoptosis Mitochondria are central to the regulation of apoptosis, the programmed cell death process, which plays a pivotal role in cholestatic liver injury. The review ...

Mirum Pharmaceuticals (NASDAQ:MIRM) received breakthrough therapy designation for volixibat, a therapeutic candidate for ...

Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for Kayfanda ...

Kayfanda® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for ...

Mirum Pharmaceuticals's volixibat was granted breakthrough therapy designation by the Food and Drug Administration as a potential treatment for cholestatic pruritus for those with primary biliary ...

Ipsen has also received E.U. approval for Iqirvo ® (elafibranor) for Primary Biliary Cholangitis, another important treatment in the company’s leading rare cholestatic liver disease portfolio.

Livmarli is a novel, orally administered, minimally-absorbed ileal bile acid transporter (“IBAT”) inhibitor (“IBATi”) that is approved for the treatment of cholestatic pruritus in patients ...